Načítá se...
Cost-utility analysis of imrecoxib compared with celecoxib for patients with osteoarthritis
BACKGROUND: The objective of this study is to compare the long-term cost-utility of imrecoxib and celecoxib for patients with osteoarthritis (OA) from the perspective of the Chinese healthcare system. METHODS: An economic model was built based on the model from the National Institute for Health and...
Uloženo v:
| Vydáno v: | Ann Transl Med |
|---|---|
| Hlavní autoři: | , , , , , , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
AME Publishing Company
2021
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8105807/ https://ncbi.nlm.nih.gov/pubmed/33987273 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.21037/atm-21-290 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|